PMID- 25548841
OWN - NLM
STAT- MEDLINE
DCOM- 20150313
LR  - 20220408
IS  - 1524-4725 (Electronic)
IS  - 1076-0512 (Linking)
VI  - 41 Suppl 1
DP  - 2015 Jan
TI  - Patient satisfaction and safety with aesthetic onabotulinumtoxinA after at least 
      5 years: a retrospective cross-sectional analysis of 4,402 glabellar treatments.
PG  - S19-28
LID - 10.1097/DSS.0000000000000275 [doi]
AB  - BACKGROUND: Despite extensive clinical experience with onabotulinumtoxinA, few 
      data exist on patient satisfaction or safety with continuous treatment. 
      OBJECTIVE: This international multicenter study evaluated patient satisfaction 
      and safety with long-term continuous facial aesthetic treatment with 
      onabotulinumtoxinA. METHODS: Retrospective chart review with a cross-sectional 
      design was used to assess onabotulinumtoxinA treatment, including dosing, 
      concomitant facial aesthetic medications and procedures, and adverse events 
      (AEs). Validated Facial Line Satisfaction Questionnaire, Self-Perception of Age 
      measure, and Facial Line Outcomes questionnaire instruments, and a de novo 
      questionnaire were used to determine patient satisfaction. RESULTS: A total of 
      207 patients consisted of the intent-to-treat population, with 194 in the per 
      protocol analyses. Patients received a total of 4,402 glabellar treatments over a 
      mean of 9.1 years, with a mean dose of 21.6 U per treatment. Overall, 92.3% of 
      patients were mostly or very satisfied. Among the 89.7% of patients who reported 
      looking younger, the mean perceived age was 6.9 years younger. Documented AEs 
      were infrequent, mostly mild in severity, and declined in frequency over time. 
      LIMITATIONS: This population was self-selecting as they chose to continue 
      treatment for 5 or more years to be eligible. CONCLUSION: Continuous treatment 
      with onabotulinumtoxinA for a mean of 9.1 years was associated with very high 
      patient satisfaction.
FAU - Trindade de Almeida, Ada
AU  - Trindade de Almeida A
AD  - *Hospital Do Servidor Publico Municipal, Sao Paulo, Brazil; daggerCarruthers Clinical 
      Research, Vancouver, British Columbia, Canada; double daggerAesthetic Solutions, Chapel Hill, 
      North Carolina;  section signGoldman, Butterwick, Fitzpatrick, Groff and Fabi: Cosmetic Laser 
      Dermatology, San Diego, California;  ||Allergan, Inc., Irvine, California.
FAU - Carruthers, Jean
AU  - Carruthers J
FAU - Cox, Sue Ellen
AU  - Cox SE
FAU - Goldman, Mitchel P
AU  - Goldman MP
FAU - Wheeler, Sarah
AU  - Wheeler S
FAU - Gallagher, Conor J
AU  - Gallagher CJ
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Dermatol Surg
JT  - Dermatologic surgery : official publication for American Society for Dermatologic 
      Surgery [et al.]
JID - 9504371
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Aged
MH  - Botulinum Toxins, Type A/adverse effects/*therapeutic use
MH  - Cosmetic Techniques
MH  - Cross-Sectional Studies
MH  - Female
MH  - Forehead
MH  - Humans
MH  - Long-Term Care
MH  - Male
MH  - Middle Aged
MH  - Neuromuscular Agents/adverse effects/*therapeutic use
MH  - *Patient Satisfaction
MH  - Retrospective Studies
MH  - Skin Aging
EDAT- 2014/12/31 06:00
MHDA- 2015/03/17 06:00
CRDT- 2014/12/31 06:00
PHST- 2014/12/31 06:00 [entrez]
PHST- 2014/12/31 06:00 [pubmed]
PHST- 2015/03/17 06:00 [medline]
AID - 00042728-201501001-00005 [pii]
AID - 10.1097/DSS.0000000000000275 [doi]
PST - ppublish
SO  - Dermatol Surg. 2015 Jan;41 Suppl 1:S19-28. doi: 10.1097/DSS.0000000000000275.